Antares Pharma (Antares Pharma) Long-Term Capital Lease Obligation : $5.1 Mil (As of Mar. 2022)

View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Long-Term Capital Lease Obligation?

Antares Pharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2022 was $5.1 Mil.

Antares Pharma's quarterly Long-Term Capital Lease Obligation declined from Sep. 2021 ($4.6 Mil) to Dec. 2021 ($4.6 Mil) but then increased from Dec. 2021 ($4.6 Mil) to Mar. 2022 ($5.1 Mil).

Antares Pharma's annual Long-Term Capital Lease Obligation declined from Dec. 2019 ($5.4 Mil) to Dec. 2020 ($4.8 Mil) and declined from Dec. 2020 ($4.8 Mil) to Dec. 2021 ($4.6 Mil).

Antares Pharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Antares Pharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Long-Term Capital Lease Obligation Chart

Antares Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.44

4.82

4.58

Antares Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															4.60	4.55	4.61	4.58	5.06

Antares Pharma (NAS:ATRS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Antares Pharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Antares Pharma (Antares Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Princeton South, Suite 300, Ewing, NJ, USA, 08628

Website

https://www.antarespharma.com

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart	director	C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson	officer: See Remarks	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell	officer: Executive Vice President & CFO	C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity	director
Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob	director	C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham	officer: See Remarks	315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth	director
Robert F Apple	director, officer: President & CEO	C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson	director
Jacques Gonella	director	C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi	officer: EVP, Chief Medical Officer	106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn	officer: VP/Controller & Interim CFO	C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447